ECA Marcellus Trust I (ECTM)
OTCMKTS · Delayed Price · Currency is USD
0.5900
-0.0025 (-0.42%)
Jun 30, 2026, 3:29 PM EST
ECA Marcellus Trust I Revenue
ECA Marcellus Trust I had revenue of $1.79M in the quarter ending March 31, 2026, with 40.19% growth. This brings the company's revenue in the last twelve months to $4.28M, up 51.36% year-over-year. In the year 2025, ECA Marcellus Trust I had annual revenue of $3.76M with 73.05% growth.
Revenue (ttm)
4.28M
Revenue Growth
+51.36%
P/S Ratio
2.44
Revenue / Employee
2.14M
Employees
2
Market Cap
10.43M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.76M | 1.59M | 73.05% |
| Dec 31, 2024 | 2.18M | -709.58K | -24.60% |
| Dec 31, 2023 | 2.88M | -8.74M | -75.18% |
| Dec 31, 2022 | 11.62M | 5.33M | 84.63% |
| Dec 31, 2021 | 6.30M | 4.59M | 269.63% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EXCO Resources | 394.03M |
| Unit Corporation | 102.96M |
| Trek Resources | 15.44M |
| Royale Energy | 1.86M |
| Cyber App Solutions | 586.70K |
| Norris Industries | 286.09K |
| Biloxi Marsh Lands | 75.50K |
| PetroSun | 992.00 |
ECA Marcellus Trust I News
- 6 weeks ago - ECA Marcellus Trust I Announces Quarterly Distribution - Business Wire
- 1 year ago - Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel) - Business Wire
- 2 years ago - ECA Marcellus Trust I Announces There Will Be No Quarterly Distribution - Business Wire
- 2 years ago - Neurotech Pharmaceuticals, Inc. Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel) - Business Wire
- 2 years ago - Kontron introduces the XMC-ETH6 - Business Wire
- 6 years ago - ECA Marcellus Trust I Provides Update on NYSE Delisting - Business Wire